LNAnteCHIX:LNAP 84 EBITDA Margin % is 16.86% as of Dec. 2025, which is 11% below its 10-year median of 18.88. GuruFocus rates CHIX:LNAP with a GF Score™ of 84/100 and a GF Value™ of €26.47. The stock has 9 warning signs investors should review. Among 668 Healthcare Providers & Services companies, LNAnte ranks better than 67.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. LNAnte's EBITDA for the
six
months ended in Dec. 2025 was €78.6 Mil. LNAnte's Revenue for the
six
months ended in Dec. 2025 was €466.2 Mil. Therefore, LNAnte's EBITDA margin for the quarter that ended in Dec. 2025 was 16.86%.
LNAnte (CHIX:LNAp) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
LNAnte EBITDA Margin % Related Terms
LNAnte EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for LNAnte's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:LNAP vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, LNAnte's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LNAnte EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LNAnte's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where LNAnte's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNAnte (CHIX:LNAP) has a EBITDA Margin % of 16.86% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LNAnte and its competitors. This is 11% below median its historical median of 18.88. Over the past decade, LNAnte's EBITDA Margin % has ranged from 9.66 to 21.43. According to the industry distribution chart, LNAnte ranks #219 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 32.8%.
Is LNAnte's EBITDA Margin % too high?
LNAnte's current EBITDA Margin % of 16.86% is 11% below median its 10-year median of 18.88. Over the past 10 years, this metric has ranged from a low of 9.66 to a high of 21.43. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. LNAnte's value of 16.86% is 65.1% above this industry median. Based on the distribution chart, LNAnte ranks #219 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, LNAnte has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does LNAnte's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, LNAnte ranks #219 out of 668 companies for EBITDA Margin %. This puts LNAnte in the upper half of its industry. The industry median EBITDA Margin % is 10.21. LNAnte's value of 16.86% is 65.1% above this benchmark. Historically, LNAnte's own EBITDA Margin % has ranged from 9.66 to 21.43 over the past decade. While the company's 10-year median is 18.88 vs. the industry median of 10.21, LNAnte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LNAnte's current EBITDA Margin % of 16.86% is 65.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LNAnte and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LNAnte's current EBITDA Margin % is 16.86%, which is 11% below median its own 10-year median of 18.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LNAnte stock overvalued right now?
LNAnte (CHIX:LNAP) has a current EBITDA Margin % of 16.86%. The stock's GF Value™ is €26.47, compared to a current price of €29.60 — trading 11.8% above its estimated fair value. The current EBITDA Margin % is 16.86%, which is 11% below median its 10-year median of 18.88 and 65.1% above the Healthcare Providers & Services industry median of 10.21. LNAnte's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For LNAnte (CHIX:LNAP), the current EBITDA Margin % is 16.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LNAnte (CHIX:LNAP) Overvalued in 2026?
Based on GuruFocus' analysis, LNAnte stock appears to be overvalued.
The current stock price of €29.60 is trading 11.8% above its estimated GF Value™ of €26.47.
Key valuation signals for CHIX:LNAP:
EBITDA Margin %: 16.86% (11% below median its 10-year median of 18.88)
GF Value™: €26.47 vs. price of €29.60 (11.8% above fair value)
Industry Position: 65.1% above the Healthcare Providers & Services median (#219 of 668)
No single metric tells the full story. See the CHIX:LNAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LNA Sante SA is engaged in the management and operation of retirement homes, nursing homes, follow-up care clinics, rehabilitation centers, centers for the disabled and handicapped ageing.
84GF Score
Get the complete analysis for CHIX:LNAP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:LNAP has been successfully added to your 
